Novo Nordisk Agrees to Buy Cardior for Up to €1 Billion

Soaring demand for obesity drugs is driving Novo’s dealmaking
Danish drugmaker wants to expand its cardiovascular treatments

Novo Nordisk said it will make an upfront payment for Cardior Pharmaceuticals. — Novo Nordisk said it will make an upfront payment for Cardior Pharmaceuticals.
Photographer: Christian Schultz/picture alliance/Getty Images

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Naomi Kresge and Deirdre Hipwell

March 25, 2024 at 10:15 AM UTC

Updated on

March 25, 2024 at 11:06 AM UTC

This article is for subscribers only.

Novo Nordisk A/S agreed to buy Cardior Pharmaceuticals for up to €1 billion ($1.1 billion) as the Danish maker of weight-loss drugs continues to expand into treatments for cardiovascular disease.

The maker of hit obesity drug Wegovy said Monday it will make an upfront payment for Cardior with additional payouts dependent on reaching certain milestones.